Table 2.
Shared genetic abnormalities between sorted blasts and pDCs from pDC-AML
| Patient | Shared variants and cytogenetic abnormalities | VAF, % | |||
|---|---|---|---|---|---|
| Blasts | pDCs | Monocytes | T cells | ||
| 1 | RUNX1 D198G | 48.9 | 48.5 | NA | NA |
| NRAS G12D | 27.9 | 35.3 | |||
| WT1 R380Tfs*5 | 13.9 | 8.2 | |||
| FLT3 I836del | 10.1 | 5.6 | |||
| FLT3D835Y | 2.2 | 0.2 | |||
| 2 | SRSF2 P95H | 39.9 | 52.8 | NA | NA |
| ASXL1 E635Rfs*15 | 19.0 | 22.2 | |||
| KITD816V | 4.0 | 2.0 | |||
| 3 | RUNX1 A435Gfs*165 | 37.6 | 44.2 | NA | NA |
| 4 | RUNX1 L98fs*24 | 45.2 | 44.7 | NA | 0 |
| DNMT3A G543C | 52.5 | 47.5 | 0 | ||
| DNMT3AI715Gfs*69 | 19.9 | 20.0 | 0 | ||
| 5 | RUNX1 D62Rfs*11 | 3.2 | 2.0 | 3.9 | NA |
| TET2 Q743* | 82.6 | 96.4 | 50.4 | ||
| TET2 R1465* | 14.9 | 3.5 | 50.1 | ||
| SRSF2 P95L | 37.8 | 49.3 | 27.3 | ||
| CBL L380P | 27.3 | 19.3 | 21.3 | ||
| NRAS G12V | 7.8 | 1.4 | 17.0 | ||
| KRAS G12R | 1.5 | 0.1 | 2.7 | ||
| Trisomy 8 | 22.7 | 21 | 85 | 0 | |
| 6 | JARID2 E50Afs*8 | 86.7 | 88.3 | NA | NA |
| 7 | RUNX1 V164_G165reSWGCP | 34 | 35 | NA | 0 |
| PHF6 C283F | 97 | 98 | 0 | ||
| SRSF2 P96L | 50 | 53 | 0 | ||
| TET2 Q964* | 47 | 52 | 0 | ||
| ASXL1 P701fs*2 | 46 | 50 | 0 | ||
| NF1 S2309T | 30 | 29 | 0 | ||
| NF1 P2310N | 30 | 29 | 0 | ||
| 8 | CRLF2 fusion | 27.5 | 25 | 19.5 | 0 |
| 9 | Deletion of 7q31 | 98 | 98 | 99 | 0 |
NA, sorted population not available for analysis.